STOCK TITAN

Integra Lifesciences Hldgs Cp - IART STOCK NEWS

Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.

Overview

Integra Lifesciences Holdings Corp (IART) is a New Jersey-based medical technology company that designs and manufactures a broad spectrum of advanced medical devices and surgical instruments. Serving global markets, Integra focuses on regenerative therapies, orthopedic extremity surgery, and neurosurgical applications. The firm operates through its two primary segments: Codman Specialty Surgical and Tissue Technologies, each addressing specific surgical needs with precision and innovative solutions.

Core Business Areas

Integra is dedicated to reducing uncertainty in the operating room by providing reliable, high-quality products for use in:

  • Orthopedic Extremity Surgery: Devices and implants engineered for improved outcomes in spine, foot and ankle, hand and wrist, shoulder and elbow procedures, as well as tendon and peripheral nerve protection and repair.
  • Neurosurgery: A comprehensive portfolio of implants, devices, instruments, and systems used in neurosurgery, neurotrauma management, continuous intracranial pressure monitoring, and neuromonitoring, leveraging advanced data presentation and MR conditional technology.
  • Regenerative and Tissue Technologies: Innovative solutions for reconstructive and general surgeries, focusing on tissue repair and regeneration that enhance patient recovery and surgical precision.

Market Position and Significance

Integra stands as a significant player in the medical device industry through its commitment to innovation and high-quality manufacturing standards. Its diversified product portfolio not only addresses a wide range of surgical challenges but also enhances patient care by enabling surgeons to focus better on treatment outcomes. The company’s practices, which include strategic acquisitions and investments in state-of-the-art manufacturing facilities, position it within a highly competitive landscape where operational excellence and product reliability are paramount.

Operational Excellence and Supply Chain

With a focus on streamlining manufacturing processes and ensuring the highest quality systems, Integra continuously refines its operational model. Its integrated supply chain and adherence to rigorous quality standards enable it to manage regulatory requirements while efficiently delivering innovative surgical solutions. The emphasis on quality, reliability, and a diversified manufacturing base is key to supporting robust market demand and maintaining consistent product availability across domestic and international markets.

Innovation and Expertise

Driven by the goal of restoring patients' lives, Integra leverages its deep industry expertise to innovate treatment pathways across surgical, neurologic, and regenerative care. Its commitment to research, development, and the integration of technological advancements ensures that surgeons and healthcare professionals have access to cutting-edge tools and instruments designed to meet the evolving demands of modern medicine.

Competitive Landscape

In a competitive market that features several major medical technology firms, Integra distinguishes itself through its targeted product development and clear focus on improving clinical outcomes. It addresses the challenges of integrating new technologies with traditional surgical practices, emphasizing innovation while maintaining rigorous quality control and operational consistency.

Investor and Analyst Insights

For investors and market analysts, Integra offers a detailed narrative of operational resilience and strategic execution. The company’s clear segmentation into specialty surgical and tissue technologies provides transparency into its revenue streams and market focus. Its global presence, combined with a commitment to operational excellence, ensures that its products remain at the forefront of surgical innovation and patient care.

Rhea-AI Summary
Integra LifeSciences CFO to present at Wells Fargo Healthcare Conference on September 6, 2023 at 1:30 p.m. EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation will release its second quarter 2023 financial results on July 27, 2023. A conference call will be hosted by the management team at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences earnings
Rhea-AI Summary
Integra LifeSciences completes patient enrollment in the DuraSorb U.S. IDE clinical study for two-stage breast reconstruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported first quarter 2023 revenues of $380.8 million, marking a 1.1% increase year-over-year on a reported basis and 4.6% growth organically. GAAP earnings per diluted share were $0.29, down from $0.39 in the previous year, with adjusted earnings remaining steady at $0.74. The company reaffirmed its full-year revenue guidance of $1,602 to $1,620 million and adjusted EPS guidance of $3.43 to $3.51. Segment performance showed $248.1 million in revenues from Codman Specialty Surgical, while Tissue Technologies generated $132.7 million. Key highlights include strong demand across product lines and a successful launch of new products. The company also strengthened its balance sheet and returned value to shareholders through a $150 million share repurchase program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
-
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its first quarter 2023 financial results on April 26, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the earnings.

Investors can access the live webcast on the company's investor website. A replay of the call will be available afterward. Integra is renowned for its regenerative tissue technologies and neurosurgical solutions, providing high-quality products that support optimal patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences earnings
Rhea-AI Summary

Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its 2022 financial results, revealing fourth quarter revenues of $398.0 million, a 1.8% decrease year-over-year, but a 2.9% organic growth. GAAP earnings per diluted share rose to $0.63 from $0.53 in Q4 2021. For the full year, revenues reached $1,557.7 million, a 1.0% increase, with GAAP EPS at $2.16. The company provided guidance for 2023, expecting revenues of $1,602 million to $1,620 million and adjusted EPS between $3.43 and $3.51, indicating optimism for growth as markets recover from COVID-19 impacts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags

FAQ

What is the current stock price of Integra Lifesciences Hldgs Cp (IART)?

The current stock price of Integra Lifesciences Hldgs Cp (IART) is $19.57 as of April 4, 2025.

What is the market cap of Integra Lifesciences Hldgs Cp (IART)?

The market cap of Integra Lifesciences Hldgs Cp (IART) is approximately 1.5B.

What are the primary business segments of Integra Lifesciences?

Integra operates primarily through its Codman Specialty Surgical and Tissue Technologies segments, focusing on advanced medical devices for surgical applications.

How does Integra support surgical procedures?

By offering innovative devices and implants for orthopedic, neurosurgical, and regenerative procedures, Integra helps reduce uncertainty in the operating room and improves patient outcomes.

What types of products does Integra develop?

Integra develops a wide range of medical devices including surgical instruments, implants, and monitoring systems designed for orthopedic extremity surgeries, neurosurgery, and tissue repair.

Which markets does Integra serve?

Integra serves a diverse range of markets, including domestic sales in the United States and international markets across Europe, Asia Pacific, and other regions.

How does Integra differentiate itself in a competitive landscape?

The company differentiates itself through a robust portfolio of innovative products, strategic operational execution, and high-quality manufacturing practices, ensuring reliability and precision.

What role does innovation play at Integra?

Innovation is central to Integra's mission; the company continually advances surgical techniques and treatment pathways through research, development, and the integration of the latest technology.

How is Integra’s supply chain managed?

Integra maintains a rigorous supply chain with strategic investments in state-of-the-art manufacturing facilities, ensuring that product quality and regulatory compliance are consistently met.

What common investor concerns are addressed by Integra?

Investors typically seek clarity on the company’s operational efficiency, regulatory compliance, product innovation, and market positioning, all of which Integra addresses through transparent business segmentation and strategic investments.
Integra Lifesciences Hldgs Cp

Nasdaq:IART

IART Rankings

IART Stock Data

1.46B
66.16M
14.24%
91.53%
5.06%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PRINCETON